CranioSense, Inc.
CranioSense, Inc. is a clinical stage company focused on revolutionizing the measurement of intracranial pressure (ICP) with their innovative IPASS technology. This non-invasive solution aims to provide rapid and safe ICP assessments, addressing the critical need for better management of traumatic brain injury (TBI) and other conditions associated with elevated cranial pressure. By eliminating the need for invasive procedures, CranioSense is poised to significantly improve patient outcomes and healthcare practices.
CranioSense, Inc.
CranioSense, Inc. is currently seeking investment
CranioSense, Inc. is seeking a investment in the range of
What We Do
IPASS is a non-invasive technology developed by CranioSense to measure intracranial pressure in seconds. It uses a patch on the forehead, two clip-on sensors, and a handheld device, eliminating the need for drilling into the skull or inserting sensors into the brain.
Application Area
Key People
News & Updates
CranioSense has entered into a collaboration and licensing agreement with Vivonics Inc. to further develop and commercialize their IPASS technology.
CranioSense was recognized at the M2D2 2020 event.
CranioSense received recognition at the Tech Connect Innovation 2022 event.
CranioSense was acknowledged by TMC Innovation for their innovative solutions.
CranioSense participated in the MassChallenge program, highlighting their innovative approach.
CranioSense is part of the Northeastern Venture Mentoring Network, supporting their growth and innovation.